PT  - JOURNAL ARTICLE
AU  - Danielle A. Schmid
AU  - Tao Yang
AU  - Michael Ogier
AU  - Ian Adams
AU  - Yatin Mirakhur
AU  - Qifang Wang
AU  - Stephen M. Massa
AU  - Frank M. Longo
AU  - David M. Katz
TI  - A TrkB Small Molecule Partial Agonist Rescues TrkB Phosphorylation Deficits and Improves Respiratory Function in a Mouse Model of Rett Syndrome
AID  - 10.1523/JNEUROSCI.0865-11.2012
DP  - 2012 Feb 01
TA  - The Journal of Neuroscience
PG  - 1803--1810
VI  - 32
IP  - 5
4099  - http://www.jneurosci.org/content/32/5/1803.short
4100  - http://www.jneurosci.org/content/32/5/1803.full
SO  - J. Neurosci.2012 Feb 01; 32
AB  - Rett syndrome (RTT) results from loss-of-function mutations in the gene encoding the methyl-CpG-binding protein 2 (MeCP2) and is characterized by abnormal motor, respiratory and autonomic control, cognitive impairment, autistic-like behaviors and increased risk of seizures. RTT patients and Mecp2-null mice exhibit reduced expression of brain-derived neurotrophic factor (BDNF), which has been linked in mice to increased respiratory frequency, a hallmark of RTT. The present study was undertaken to test the hypotheses that BDNF deficits in Mecp2 mutants are associated with reduced activation of the BDNF receptor, TrkB, and that pharmacologic activation of TrkB would improve respiratory function. We characterized BDNF protein expression, TrkB activation and respiration in heterozygous female Mecp2 mutant mice (Het), a model that recapitulates the somatic mosaicism for mutant MECP2 found in typical RTT patients, and evaluated the ability of a small molecule TrkB agonist, LM22A-4, to ameliorate biochemical and functional abnormalities in these animals. We found that Het mice exhibit (1) reduced BDNF expression and TrkB activation in the medulla and pons and (2) breathing dysfunction, characterized by increased frequency due to periods of tachypnea, and increased apneas, as in RTT patients. Treatment of Het mice with LM22A-4 for 4 weeks rescued wild-type levels of TrkB phosphorylation in the medulla and pons and restored wild-type breathing frequency. These data provide new insight into the role of BDNF signaling deficits in the pathophysiology of RTT and highlight TrkB as a possible therapeutic target in this disease.